Literature DB >> 19052991

Bortezomib-associated tumor lysis syndrome in multiple myeloma.

Michelle Furtado, Simon Rule.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19052991     DOI： 10.1080/10428190802484099

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

1.  Tumor Lysis Syndrome in Multiple Myeloma: An Increasingly Recognized Risk-A Report of Seven Cases.

Authors:  Abhijai Singh; Shweta Gupta; Barbara Yim; Romy Thekkekara
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-03       Impact factor: 0.900

Review 2.  Tumor lysis syndrome: new challenges and recent advances.

Authors:  F Perry Wilson; Jeffrey S Berns
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

Review 3.  Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology.

Authors:  Gabriela Lupușoru; Ioana Ailincăi; Georgiana Frățilă; Oana Ungureanu; Andreea Andronesi; Mircea Lupușoru; Mihaela Banu; Ileana Văcăroiu; Constantin Dina; Ioanel Sinescu
Journal:  Biomedicines       Date:  2022-04-28

Review 4.  Proteasome inhibitors in the treatment of multiple myeloma.

Authors:  J J Shah; R Z Orlowski
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

5.  Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.

Authors:  Masahiro Kondo; Yuji Hotta; Karen Yamauchi; Akimasa Sanagawa; Hirokazu Komatsu; Shinsuke Iida; Kazunori Kimura
Journal:  BMC Cancer       Date:  2020-11-17       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.